.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,750,244

« Back to Dashboard

Details for Patent: 6,750,244

Title: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
Abstract:Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
Inventor(s): Mueller; Alan L. (Salt Lake City, UT), Moe; Scott T. (Salt Lake City, UT)
Assignee: NPS Pharmaceuticals, Inc. (Salt Lake City, UT)
Filing Date:Apr 02, 2001
Application Number:09/825,373
Claims:1. A compound of Formula VIII: ##STR189##

wherein: Z is selected from the group consisting of: --S--CH.sub.2 --, --O--CH.sub.2 --, --O--, and --S--; X.sup.1 and X.sup.2 are independently selected from the group consisting of F, --Cl, --CH.sub.3, --OH, and lower O-alkyl in the 1-, 3-, 7-, or 9-substituent positions; m is independently an integer from 0 to 2, provided that at least one of m is not 0; --NHR is selected from the group consisting of --NH.sub.2, --NHCH.sub.3, and --NHC.sub.2 H.sub.5 ; R.sup.1 is selected from the group consisting of --H, alkyl, hydroxyalkyl, --OH, --O-alkyl, and --O-acyl, and R.sup.2 is selected from the group consisting of --H, alkyl, hydroxyalkyl, and pharmaceutically acceptable salts and complexes thereof, wherein the compound is active at an NMDA receptor.

2. A compound of Formula VIII: ##STR190## wherein: Z is selected from the group consisting of: --S--CH.sub.2 --, --O--CH.sub.2 --, --O--, and --S--; X.sup.1 and X.sup.2 are independently selected from the group consisting of: F, --Cl, --CH.sub.3, --OH, and lower O-alkyl in the 1-, 3-, 7-, or 9-substituent positions; m is independently an integer from 1 to 2; --NHR is selected from the group consisting of --NH.sub.2, --NHCH.sub.3, and --NHC.sub.2 H.sub.5 ; R.sup.1 is selected from the group consisting of --H, alkyl, hydroxyalkyl, --OH, --O-alkyl, and --O-acyl, and R.sup.2 is selected from the group consisting of --H, alkyl, hydroxyalkyl, and pharmaceutically acceptable salts and complexes thereof, wherein the compound is active at an NMDA receptor.

3. A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.

4. A method of treating a patient having a neurological disease or disorder comprising administering a compound of Formula VIII: ##STR191##

wherein: Z is selected from the group consisting of: --O--, --O--CH.sub.2 --, --S--CH.sub.2, and --S--; X.sup.1 and X.sup.2 are independently selected from the group consisting of --F, --Cl, --CH.sub.3, --OH, and lower O-alkyl in the 1-, 3-, 7-, or 9-substituent positions; m is independently an integer from 0 to 2; --NHR is selected from the group consisting of --NH.sub.2, --NHCH.sub.3, and --NHC.sub.2 H.sub.5 ; R.sup.1 is selected from the group consisting of --H, alkyl, hydroxyalkyl, --OH, --O-alkyl, and --O-acyl, and R.sup.2 is selected from the group consisting of --H, alkyl, hydroxyalkyl, and pharmaceutically acceptable salts and complexes thereof, wherein the compound is active at an NMDA receptor.

5. A method of treating a patient having a neurological disease or disorder comprising administering a compound of a structure selected from the group consisting of: ##STR192##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc